摘要
目的:探讨异甘草酸镁联合恩替卡韦治疗慢性乙型肝炎有效性与安全性。方法:将2018年3月—2020年3月在该院治疗的180例慢性乙型肝炎患者均分为两组。对照组(n=90)采用异甘草酸镁治疗,观察组(n=90)在对照组的基础上联合恩替卡韦治疗,观察并分析两组的治疗成果。结果:观察组临床疗效总有效率相较于对照组临床疗效总有效率更高,差异有统计学意义(χ^(2)=4.063,P <0.05)。观察组不良反应发生率相较于对照组不良反应发生率较低,差异有统计学意义(χ^(2)=4.390,P <0.05)。乙肝病毒DNA(HBV-DNA)转阴率方面比较,治疗6、12个月后观察组HBV-DNA转阴率相较于对照组更高,差异有统计学意义(P<0.05)。肝纤维化水平方面比较,观察组HA、Ⅳ-C、PⅢNP、LN水平相较于对照组更优,差异有统计学意义(t=8.256、64.260、65.341、23.322,P<0.05)。血清天冬氨酸转氨酶(aspartate aminotransferase,AST)、丙氨酸转氨酶(alanine aminotransferase,ALT)、总胆红素(total bilirubin,TBil)水平方面比较,观察组血清AST、ALT、TBil水平相较于对照组更低,差异有统计学意义(t=6.123、25.224、34.557,P <0.05)。肝脏储备功能量化(Child-Pugh)评分方面比较,观察组Child-Pugh评分相较于对照组更低,差异有统计学意义(t=47.371,P<0.05)。免疫功能指标水平方面,观察组CD3+、CD4+、CD4+/CD8+水平相较于对照组更高,差异有统计学意义(t=40.186、13.133、12.775,P <0.05)。结论:对于慢性乙型肝炎患者采用异甘草酸镁联合恩替卡韦治疗,安全性高、疗效显著,可以改善患者的生活质量,值得推广应用。
Objective: To explore the effectiveness and safety of magnesium isoglycyrrhizinate combined with entecavir in the treatment of chronic hepatitis B. Methods: From March 2018 to March 2020, the 180 patients with chronic hepatitis B who were treated in this hospital were divided into two groups. The control group(n = 90) was treated with magnesium isoglycyrrhizinate, and the observation group(n = 90) was treated with entecavir on the basis of the control group. The treatment results of the two groups were observed and analyzed. Results: The total effective rate of clinical curative effect in the observation group was higher than the total effective rate of clinical curative effect in the control group, with a statistical significant difference(χ^(2)= 4.063, P < 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, with a statistical significant difference(χ^(2)= 4.390, P < 0.05). Compared with the negative rate of HBV-DNA, after 6 and 12 months of treatment, the HBV-DNA conversion rate of the observation group was higher than that of the control group, with a statistical significant difference(P<0.05). Compared with the level of liver fibrosis, the levels of HA, Ⅳ-C, P Ⅲ NP and LN in the observation group were better than those in the control group, with a statistical significant difference(t =8.256, 64.260, 65.341, 23.322, P<0.05). Comparison of serum aspartate aminotransferase(AST), alanine aminotransferase(ALT), and total bilirubin(TBil) levels. Serum AST, ALT, and TBil levels in the observation group were lower than those in the control group, the difference was statistically significant(t =6.123, 25.224, 34.557, P<0.05). Compared with the quantification of liver reserve function(Child-Pugh) score, the Child-Pugh score of the observation group was lower than that of the control group, the difference was statistically significant(t =47.371, P<0.05). In terms of immune function index levels, CD3+, CD4+, CD4+/CD8+ levels in the observation group were higher than those in the control group, with a statistical significant difference(t =40.186, 13.133, 12.775, P<0.05). Conclusion: For patients with chronic hepatitis B, the treatment of magnesium isoglycyrrhizinate combined with entecavir has high safety and significant efficacy, can improve the quality of life of patients, and is worthy of promotion and application.
作者
李姣
杜景海
LI Jiao;DU Jinghai(Department of liver disease,Chaoyang fourth hospital,Chaoyang,Liaoning Chaoyang 122000)
出处
《中国药物滥用防治杂志》
CAS
2021年第3期327-331,共5页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
异甘草酸镁
恩替卡韦
慢性乙型肝炎
有效性
安全性
Magnesium isoglycyrrhizinate
Entecavir
Chronic hepatitis B
Effectiveness
Safety
